Jul. 2 at 8:12 PM
Chardan Research named Arrowhead Pharmaceuticals its top biotech and pharma pick for 2026, reiterating a Buy rating and a
$90 price target. The firm expects the key catalyst to be Phase 3 SHASTA-3/4 data for plozasiran in severe hypertriglyceridemia during Q3 2026, with management expressing confidence in durable triglyceride reductions and a favorable long-term safety profile.
Chardan also highlighted comments from Cleveland Clinic cardiologist Steven Nissen, who said he prefers plozasiran over recently approved Tryngolza due to its tolerability, longer duration and potential efficacy. Beyond plozasiran, the firm sees additional upside from zodasiran, which could be filed in 2027, and ARO-DIMER-PA, a dual-target siRNA candidate designed to lower both LDL cholesterol and triglycerides.
The bullish outlook follows Arrowhead's recent quarterly results, where the company reported
$74 million in Q2 2026 revenue and a
$0.93 per-share loss, both better than analyst expectations.
$ARWR